ArticleCell reports. Medicine2025
BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF
Abstract read
In one paragraph
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trends and hotspots in research related to tumor immune escape: bibliometric analysis and future perspectives.Frontiers in immunology · 2025Pooled it
- Practical management of BRAF inhibitors in glioma: toxicity and resistance.CNS oncology · 2026Review
- Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Dual targeting of interlocked PTK2B and MAPK signaling triggers synergistic ferroptosis via autophagic flux disruption in BRAFCell communication and signaling : CCS · 2026Article
- Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.Journal of experimental & clinical cancer research : CR · 2026Article
- The future of targeted therapies for pediatric central nervous system tumors.Neuro-oncology advances · 2026Review
- A spatially resolved human glioblastoma atlas reveals distinct cellular and molecular patterns of anatomical niches.Nature communications · 2026Article
- Review
- Programmed cell death evasion in BRAF V600E-driven primary CNS tumors and thyroid cancer brain metastases.Frontiers in neurology · 2026Review
Corrections and comments
- Update of
Authors and funding
28 authors.
Yao Lulu XingDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dena PanovskaDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jong-Whi ParkDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Life Sciences, Gachon University, Incheon 21999, South Korea.
Stefan GrossauerVienna Medical Center, Medical University of Vienna, Vienna 1090, Austria.
Katharina KoeckCenter for Anatomy and Cell Biology, Medical University of Vienna, Vienna 1090, Austria.
Brandon BuiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Emon NasajpourDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jeffrey J NirschlDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Zhi-Ping FengThe Australian National University Bioinformatics Consultancy, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2600, Australia.
Pierre CheungDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, CA 94305, USA.
Pardes HabibDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ruolun WeiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jie WangDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, CA 94305, USA.
Wes ThomasonDepartment of Oncological Sciences and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Michelle MonjeDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305, USA.
Joanne XiuMedical Affairs, Caris Life Sciences Inc, Phoenix, AZ 85040, USA.
Alexander BeckCenter for Neuropathology and Prion Research, Faculty of Medicine, Ludwig-Maximilians-University, 80539 Munich, Germany.
Katharina J WeberGoethe University Frankfurt, University Hospital, Neurological Institute (Edinger Institute) and University Cancer Center (UCT), 60629 Frankfurt am Main, Germany; Frankfurt Cancer Institute, 60629 Frankfurt am Main, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Patrick N HarterCenter for Neuropathology and Prion Research, Faculty of Medicine, Ludwig-Maximilians-University, 80539 Munich, Germany.
Michael LimDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Kelly B MahaneyDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Laura M ProloDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Gerald A GrantDepartment of Neurosurgery, Duke University, Durham, NC 27708, USA.
Xuhuai JiHuman Immune Monitoring Centre, Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA 94305, USA.
Kyle M WalshDivision of Neuro-Epidemiology, Department of Neurosurgery, Duke University, Durham, NC 27708, USA.
Jean M Mulcahy LevyMorgan Adams Foundation Brain Tumor Research Program, Department of Pediatrics, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO 80045, USA.
Dolores HambardzumyanDepartment of Oncological Sciences and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Claudia K PetritschDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA; Maternal & Child Health Research Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: clpetritsch39@gmail.com.
Funding
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI MICHAEL KENNEY · 2007 to 2026
$71.4MBRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to TherapyR01NS080619 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES, CHARLES DAVID, PETRITSCH, CLAUDIA KATHARINA · 2012 to 2016
$1.8MA causal role for asymmetric cell division defects in glioma initiationR01CA164746 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETRITSCH, CLAUDIA KATHARINA · 2012 to 2016
$1.6MInvestigating ASPM regulation of asymmetric division for therapeutic opportunitiesR21NS099836 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETRITSCH, CLAUDIA KATHARINA · 2016 to 2017
$436kNCI NIH HHS P30 CA124435NCI NIH HHS R01 CA164746NINDS NIH HHS R01 NS080619NINDS NIH HHS R21 NS099836
Abstract
Resistance to v-raf murine sarcoma viral oncogene homolog B1 (BRAF) plus mitogen-activated protein kinase kinase (MEK) inhibition (BRAFi+MEKi) in BRAF
Indexed as
Brain NeoplasmsGliomaImmune Checkpoint InhibitorsMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafAnimalsB7-H1 AntigenCell Line, TumorDrug Resistance, NeoplasmHumansMiceMutationB7-H1 AntigenBRAF protein, humanCD274 protein, humanImmune Checkpoint InhibitorsMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAF and MEK inhibitor adaptationBRAF V600Ecell state transitionsGalectin-3high-grade gliomaimmune checkpoint inhibitionprogrammed death-ligand 1T cell modulation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.